Changli Wang

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Jonathan Spicer, Changli Wang, Fumihiro Tanaka et al. · Journal of Clinical Oncology · 2021 · 135 citations

Surgical Oncology, Cancer Management, Surgery +19

Acetate attenuates inflammasome activation through GPR43-mediated Ca2+-dependent NLRP3 ubiquitination

Mengda Xu, Zhengyu Jiang, Changli Wang et al. · Experimental & Molecular Medicine · 2019 · 113 citations · Full text

Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery

Hui Li, Changli Wang, Jinpu Yu et al. · Cytotherapy · 2009 · 110 citations

Anti-tumor Effect, Oncology, Cancer Immunosurveillance +8

Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment

Xiaoliang Zhao, Bhaskar Kallakury, Joeffrey Chahine et al. · Journal of Thoracic Oncology · 2019 · 107 citations · Full text

Surgical Oncology, Surgical Resection, Medicine +5

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Patrick M. Forde, Jonathan Spicer, Shun Lü et al. · Cancer Research · 2021 · 98 citations

Surgical Oncology, Cancer Management, Multimodality +18